BLOOD BORNE miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA

摘要

The differential expression of select miRNA in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls were measured. Patients (n=215) with treatment-naïve PDAC (n=77), CP with bile or pancreatic duct pathology (n=67), and controls (n=71) that had been prospectively enrolled in a Pancreatobiliary Disease Biorepository at the time of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS) were identified. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with CP and controls. Panels were derived from the differential expression of 10-candidate miRNA in plasma or bile. Differential expression of miR-10b, -155, and -106b in plasma and bile accurately distinguishes individuals with PDAC from those having CP or normal pancreata.

主权项

1. A method for treating a patient, comprising the steps of:
fractionating a sample of peripheral blood from a patient to form at least one fraction of blood; contacting the at least one fraction of blood from the patient with at least one probe specific for at least one miRNA selected from the group consisting of miR-10b, and miR-106b; detecting a signal produced by the contacting step to determine a level of at least one miRNA selected from the group consisting of: miR-10b, and miR-106b, in the sample; comparing the level of the at least one miRNA measured in the fraction to a level for miR-10b, and/or miR-106b, in a matched healthy cohort; and treating the patient for pancreatic ductal adenocarcinoma if the level of miR-10b measured in the fraction is at least 3-fold greater than the level of miR-10b measured in the matched healthy cohort.